Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

11.52 -0.41 (-3.48%)
Streaming Delayed Price Updated: 1:45 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,547
Open 11.94
Bid (Size) 11.50 (2)
Ask (Size) 11.53 (1)
Prev. Close 11.93
Today's Range 11.49 - 12.11
52wk Range 4.820 - 14.92
Shares Outstanding 23,914,879
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire

Performance

YTD
+54.98%
+54.98%
1 Month
-14.64%
-14.64%
3 Month
+9.77%
+9.77%
6 Month
+59.49%
+59.49%
1 Year
+66.64%
+66.64%

More News

Read More
Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
From Alpine Immune Sciences, Inc
Via Business Wire
Analyst Expectations for Alpine Immune Sciences's Future
Via Benzinga
Recap: Alpine Immune Sciences Q1 Earnings
Via Benzinga
Earnings Preview: Alpine Immune Sciences
Via Benzinga
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Inc. (NASDAQ: ALPN) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Earnings Scheduled For March 23, 2023
Via Benzinga
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
Via Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.